3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

US11891365B2 · kind B2 · utility

Assignee

• Valo Health, Inc. · US

Inventors

• Xiaozhang Zheng · Lexington, US
• Pui Yee Ng · Waltham, US
• Bingsong Han · Westwood, US
• Jennifer R. Thomason · Clinton, US
• Mary-Margaret Zablocki · Revere, US
• Cuixian Liu · Madison, US
• Heather Davis · Haverhill, US
• Aleksandra Rudnitskaya · Brookline, US
• David R. Lancia, Jr. · Boston, US
• Kenneth W. Bair · Chapel Hill, US
• David S. Millan · Watertown, US
• Matthew W. Martin · Arlington, US

Key dates

• Filing date: Apr 23, 2021
• Grant date: Feb 6, 2024
• Expiry date: Oct 7, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.